Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
LONDON, BOSTON, TOKYO (July 31, 2019) – By value alone, Bristol-Myers Squibb’s $74bn pending purchase of Celgene and Abbvie’s $63bn acquisition of Allergan position 2019 as a record year for pharma M&A. Similarly, Verily’s $1bn round of funding was the largest ever for a medtech company. Yet both sectors saw a substantial slowdown in the total number of M&A deals announced, and pharma doubled down on this trend with a drop in licensing activity.
Buoyant stock markets are one reason; with nearly $2bn raised by biotech flotations in Q2, investor enthusiasm continues to attract younger drug developers away from traditional M&A and partnerships. And while only eight medtech companies went public during the first half of the year, collectively they raised $1.3bn.
Venture financing also continued to provide a ready source of cash. While biotech funding dipped below 2018’s record-breaking level, the $3bn raised in Q2 indicates there is capital available. Medtech financing exceeded $2b in Q1 for the third year in a row, although the $1b raised in Q2 is lower than prior years.
“We’re seeing strong interest in biopharma and medtech companies from public and private investors, though certain areas are benefitting more than others,” said report author Amy Brown. “This likely affects the volume of acquisition and licensing deals. Barring a dramatic decline on the financial markets, it’s hard to see this trend shifting, although the potential for new drug pricing policy could make investors more jittery in the coming months.”
Additional Highlights from H1 2019:
Download a complimentary copy of the Evaluate Vantage “Pharma, Biotech & Medtech Half-Year Review 2019” at https://www.evaluate.com/2019HalfYearReview. Evaluate Vantage is the independent editorial arm of Evaluate Ltd.
Evaluate provides trusted commercial intelligence for the pharmaceutical industry and their advisors.
Our Evaluate platform offers unique and dynamic insights into asset risk and value alongside a seamless, comprehensive view of the pharmaceutical portfolio landscape.
Evaluate Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into current and future industry developments.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.